Effectiveness and Tolerability of High-Dose (23 mg/d) Versus Standard-Dose (10 mg/d) Donepezil in Moderate to Severe Alzheimer’s Disease: A 24-Week, Randomized, Double-Blind Study

BACKGROUND: Currently approved Alzheimer’s disease (AD) treatments have been reported to provide symptomatic benefit, without proven impact on clinical progression. We hypothesized that the loss of initial therapeutic benefit over time may be mitigated by higher doses of a cholinesterase inhibitor....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Farlow, Martin R., Salloway, Stephen, Tariot, Pierre N., Yardley, Jane, Moline, Margaret L., Wang, Qin, Brand-Schieber, Elimor, Zou, Heng, Hsu, Timothy, Satlin, Andrew
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3068609/
https://ncbi.nlm.nih.gov/pubmed/20678673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2010.06.019
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars